Horizon’s CEO, Dr. Darrin Disley, credits a rapid increase in exports and a strong, innovative product portfolio with the company’s 1027% revenue growth over the past five years.
Darrin commented: "It is a real testament to the strength of Horizon that we have been ranked so highly amongst such an incredible range of technology companies, and that we are the highest ranked company in the biotechnology sector. I would like to take this opportunity to thank our partners, investors, employees and customers for their support in helping to build a great business. Horizon has much more planned in the months and years to come and we’re very excited about what comes next."
David Halstead, Partner leading the Deloitte Technology Fast 50, said: “The Deloitte Technology Fast 50 gives great profile to technology companies and is internationally recognised as being one of the most important business awards in the sector”
“Making the Deloitte Technology Fast 50 is a testament to a company’s commitment to technology,” said David, who is also Deloitte Technology partner for the Cambridge region. “With its 1027% growth rate over five years, Horizon Discovery has proven that its leadership has the vision and determination to grow in competitive conditions.”
* Growth rates are all over the last five years.
The full list of this year’s winners and winner breakdown by region and sector is available at www.fast50.co.uk
About Horizon Discovery www.horizondiscovery.com/
Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. Using GENESISTM, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.
Horizon has applied GENESIS to create over 500 X-MAN™ cell lines, the world’s first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These ‘patients-in-a-test-tube’ are being used by academic and industry leaders to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the ‘right drugs’ for the ‘right patients’ based upon the unique genetic mutations that define their disease.
In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN™ derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms.
*******
PR Contact: Katie Odgaard, Zyme Communications, Tel: 07787 502 947 Email: katie.odgaard@zymecommunications.com
______________________________________________
Horizon Discovery ranks Number 22 in Deloitte Technology Fast 50
18 November 2013
Horizon Discovery today announced that it ranked Number 22 in the 2013 Deloitte Technology Fast 50, a ranking of the 50 fastest-growing technology companies in the UK. Rankings are based on percentage revenue growth over five years. Horizon grew 1027% percent during this period.